Corsano Health

Name

Corsano Health

Legal name

Corsano Health B.V.

Website

https://corsano.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Medical Wearable Patient Monitoring

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industries

Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous) (HLAHACAA), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI), Blood Pressure Monitoring (Cuff & Cuffless) (HLAHACAC), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

• Medical wearable devices
• Continuous patient monitoring
• Remote patient monitoring
• Clinical trial wearables
• Vital signs monitoring

Headquarters

HQ city

The Hague

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of CardioWatch 287 medical-grade wearable devices. CE-MDR certified and FDA 510(k) cleared for hospital and home use.
2. Cloud Platform & Software Services: Real-time patient monitoring platform with data analytics, EMR integration, and API access. Subscription-based cloud services for continuous data processing and storage.
3. Clinical Trial Services: Wearables for pharmaceutical clinical trials across cardiovascular, oncology, and stress research. Over 100 clinical trials ongoing. Services include co-development of new features and algorithms.
4. API/SDK Licensing: Access to raw and processed data via APIs and SDKs for partners to connect CardioWatch to their platforms. Third-party apps may pair and sync directly via SDKs.
5. Distribution Partnership Revenue: Revenue through exclusive distribution agreements with Medtronic (U.S.) and other regional partners. Medtronic distributes for hospital and hospital-to-home use.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels5 records

Core offering

Corsano Health designs, manufactures, and sells the CardioWatch 287-2, a CE-MDR certified and FDA 510(k) cleared medical-grade wrist-worn wearable that continuously monitors up to 19 vital parameters including heart rate, SpO2, respiratory rate, cuffless blood pressure, ECG, skin temperature, and activity. The offering bundles the hardware with a cloud platform, AI-driven clinical algorithms (cardiac arrest, AF, sepsis, deterioration), EMR integration, and API/SDK access for hospital monitoring, remote patient monitoring, and clinical trial applications.

Product overview

Corsano Health offers a unified medical-grade wearable platform centered on the CardioWatch 287-2 bracelet, which provides continuous monitoring of up to 19 vital parameters including heart rate, SpO2, respiratory rate, cuffless blood pressure, ECG, skin temperature, and activity. The ecosystem includes a Data Access API/SDK for third-party integration, a Research Portal for clinical trials, and specialized monitoring solutions for general wards, remote patient monitoring, clinical deterioration detection, and cardiac arrest. The platform delivers 38% reduction in cost of care, 70% reduction in readmissions, and 50% improvement in patient mobility through its hospital-to-home continuity model.

Differentiator

Problem solved

Functional benefit

Brands

• CardioWatch 287: Medical-grade wrist-worn multi-parameter wearable device for continuous monitoring of vital signs including heart rate, SpO2, respiratory rate, temperature, activity, and blood pressure. CE-MDR certified and FDA 510(k) cleared.
• CardioWatch

Products and services

• CardioWatch 287-2 CE-MDR certified and FDA 510(k) cleared medical-grade wrist-worn multi-parameter wearable that continuously monitors up to 19 vital parameters (heart rate, SpO2, respiratory rate, cuffless blood pressure, ECG, skin temperature, activity) using multi-sensor technology (ACC, PPG G/R/iR, ECG, Temperature, GSR), with raw data access up to 128Hz for AI/ML.
• CardioWatch 287 First-generation EU-MDR certified medical-grade wrist-worn wearable for continuous collection of physiological data including pulse rate, SpO2, respiration, temperature, and activity in healthcare and home settings.
• Corsano Data Access (API & SDK) Standalone API and SDK product that lets remote patient monitoring platforms and researchers connect to CardioWatch devices, sync raw PPG/ACC/BIOZ/ECG sensor data, and integrate with Electronic Patient Data (EPD/EMR) systems.
• Clinical Research Portal Cloud-based research platform that lets research teams create studies, configure vital sign parameters and sampling frequency, run multi-parameter analytics, track compliance metrics, and export data with data science support.
• eCOA (Electronic Clinical Outcome Assessment) Electronic clinical outcome assessment solution for pharmaceutical clinical trials that combines continuous vital signs monitoring from CardioWatch with patient-reported outcomes for medical digital therapies and decentralized trials.
• General Wards Monitoring Solution Enterprise multi-parameter monitoring solution for hospital general wards, integrating CardioWatch devices with EMR environments to support continuous monitoring, automated early warning scores, and nursing workflows.
• Remote Patient Monitoring Solution Hospital-to-home remote patient monitoring solution using the same CardioWatch device post-discharge, providing continuous monitoring with real-time feedback and personalized treatment plans for chronic disease, hypertension, and post-acute care.

Quantifiable outcome

• 38% reduction in cost of care
• +5 more outcomes

Named customers18 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature9 records

Partnerships

20 partnerships are on record, tiered core and minor.

• MedtroniccoreChannel Partner/ Reseller/ Distributor · 4 June 2026Exclusive distribution agreement for Corsano's multi-parameter wearable device in the U.S. for hospital and hospital-to-home use. Expands Medtronic's Acute Care & Monitoring portfolio into wrist-worn form factor. Builds on prior Western Europe distribution agreement. Device monitors heart rate, SpO2, respiratory rate, skin temperature, and activity.
• Netcare LimitedcoreChannel Partner/ Reseller/ Distributor · 23 November 2025Strategic partnership to roll out 24-hour health monitoring wearables across all Netcare general wards in South Africa, starting with pilot at flagship facility. Devices offer continuous patient monitoring and predictive alerts integrated into Netcare's Electronic Medical Record system.
• Roche DiagnosticscoreTechnology or IntegrationCollaboration agreement for CardioWatch EU-MDR certified patient monitoring bracelet to connect to cobas pulse, Roche's digitally enabled point-of-care platform, enabling clinical insights in point-of-care health settings.
• LifeTimeminorStrategic or Co-development PartnerEuropean research consortium for validated energetically autonomous module that harvests light through novel microchip with NB-IoT chip integration. Corsano provides vital parameter measurement capabilities.
• Watch-It ConsortiumminorStrategic or Co-development PartnerClinical validation of comprehensive care solution ('WATCH-IT') enabling 24/7 monitoring of cardio-respiratory function in patients at risk of cardiovascular events. Collaboration with Preventicus, Oslo University Hospital, and University of Gothenburg.
• DETECT ConsortiumcoreStrategic or Co-development PartnerInnovative solution to improve recognition and implementation of resuscitation assistance for cardiac arrest patients. Development project with RadboudMC, ErasmusMC, and UMC to recognize cardiac arrest with CardioWatch 287 and alert emergency services.
• Radboud University Medical CentercoreStrategic or Co-development PartnerDETECT project partner for automated cardiac arrest detection validation. 280 patients in multicenter observational study including induced circulatory arrest during TAVR and ICD procedures.
• Erasmus MCcoreStrategic or Co-development PartnerDETECT project partner for cardiac arrest detection research. Also involved in Smart in OAC AFNET 9 study with 882 participants across Germany, Poland, and Spain.
• Reinier de Graaf HospitalcoreStrategic or Co-development PartnerMULTI-VITAL and RECAMO clinical trial partner for validation of cuffless blood pressure algorithm and atrial fibrillation detection. 160 patients at catheterization laboratory.
• SepsisDialogminorStrategic or Co-development PartnerEarly sepsis detection collaboration with continuous monitoring of vital signs using CardioWatch 287-2 and advanced algorithms. Won 1st prize at healthcare hackathon for smart solution.
• Parker HealthminorStrategic or Co-development PartnerPartnership for revolutionizing patient-centric data correlation with effective clinical outcomes.
• Bangkok Dusit Medical Service (BDMS)coreChannel Partner/ Reseller/ DistributorCardioWatch launch partnership with one of the largest hospital groups in Thailand. Strategic collaboration for deployment in Thai healthcare facilities.
• Cardiology Centers Netherlands (CCN)minorStrategic or Co-development PartnerAF burden clinical trial collaboration and PPG accuracy validation study with 180 patients at outpatient cardiology clinic.
• Maria Middelares GhentminorChannel Partner/ Reseller/ DistributorFirst hospital in Belgium to use Corsano CardioWatch for cardiac patient monitoring.
• National eHealth Living Lab (NeLL)minorStrategic or Co-development PartnerCollaborative research partner for COPD patient monitoring study exploring potential of CardioWatch in monitoring patients with chronic obstructive pulmonary disease.
• JanssenminorStrategic or Co-development PartnerPharmaceutical partner for clinical trials and research collaboration in healthcare monitoring.
• CharitéminorStrategic or Co-development PartnerResearch partner for vital signs monitoring and clinical research collaboration.
• UMC UtrechtminorStrategic or Co-development PartnerDETECT project partner for cardiac arrest detection research.
• LUMC (Leiden University Medical Center)minorStrategic or Co-development PartnerDETECT project partner and COPD research collaboration with National eHealth Living Lab.
• IsalaminorStrategic or Co-development PartnerClinical trial center for cardiac arrest detection research in photoplethysmography study.

Scale indicators7 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring patch is a direct competitor in the continuous ambulatory cardiac monitoring space, targeting similar cardiology and hospital workflows with a wearable, AI-interpreted diagnostic.
• Biofourmis: Biofourmis provides AI-driven remote patient monitoring and hospital-at-home platforms, directly competing with Corsano's RPM and clinical deterioration solutions for hospital and post-discharge deployments.
• Current Health (Best Buy Health): Current Health offers a continuous remote patient monitoring platform with a wearable device for vital signs tracking, competing head-to-head with Corsano for hospital-to-home and RPM contracts.

Broad incumbents

• Masimo: Masimo is the incumbent in pulse oximetry and hospital patient monitoring, with SET pulse oximetry and growing wearable/RPM offerings that overlap directly with Corsano's SpO2 and continuous vital signs monitoring.
• Philips: Philips is both a technology partner (Wearable Sensing algorithms) and a broad incumbent in hospital patient monitoring and connected care, with overlapping capabilities in continuous vitals and sleep monitoring.
• GE HealthCare: GE HealthCare's patient monitoring portfolio (including wearable components and the Mural virtual care platform) competes in hospital continuous monitoring and RPM, with a much broader installed base and salesforce.

Emerging players

• Empatica: Empatica's EpiMonitor and EmbracePlus are FDA-cleared medical-grade wearables for continuous physiology monitoring, with overlapping use cases in cardiac and seizure detection versus Corsano's multi-parameter platform.
• Preventicus: Preventicus is both a technology partner (AF detection algorithms) and a niche competitor in cardiac arrhythmia detection via smartphone and wearable PPG, competing for the same cardiology and pharma research customers.
• Withings: Withings offers consumer- and prosumer-grade health devices including BPM Core (blood pressure), ScanWatch (ECG, SpO2), and a connected health platform, increasingly competing in RPM and continuous vitals.
• Oura: Oura's smart ring combines continuous vitals, activity, sleep and temperature tracking with an enterprise health platform, increasingly positioned for health and wellness use cases that intersect with Corsano's consumer-adjacent RPM roadmap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@corsanohealth5071
• LinkedInlinkedin.com/company/66253572

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corsano Health